Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 20
Filtrar
1.
Salud Publica Mex ; 65(4, jul-ago): 323-324, 2023 Jul 15.
Artículo en Español | MEDLINE | ID: mdl-38060886

RESUMEN

Entre los principales problemas de Salud Pública podemos identificar a la resistencia antimicrobiana (RAM), definida por la Organización Mundial de la Salud (OMS) como aquella que se produce cuando los microorganismos (bacterias, hongos, virus y parásitos) sufren cambios al verse expuestos a los antimicrobianos, resultando que los medicamentos se vuelvan ineficaces y las infecciones persistan.

2.
Viruses ; 15(12)2023 11 30.
Artículo en Inglés | MEDLINE | ID: mdl-38140595

RESUMEN

One of the priority lines of action to contain the SARS-CoV-2 pandemic was vaccination programs for healthcare workers. However, with the emergence of highly contagious strains, such as the Omicron variant, it was necessary to know the serological status of health personnel to make decisions for the application of reinforcements. The aim of this work was to determine the seroprevalence against SARS-CoV-2 in healthcare workers in a Mexican hospital after six months of the administration of the Pfizer-BioNTech vaccine (two doses, 4 weeks apart) and to investigate the association between comorbidities, response to the vaccine, and reinfections. Neutralizing antibodies against SARS-CoV-2 were determined using ELISA assays for 262 employees of Hospital Juárez de México with and without a history of COVID-19. A beta regression analysis was performed to study the associated comorbidities and their relationship with the levels of antibodies against SARS-CoV-2. Finally, an epidemiological follow-up was carried out to detect reinfections in this population. A significant difference in SARS-CoV-2 seroprevalence was observed in workers with a history of COVID-19 prior to vaccination compared to those without a history of the disease (MD: 0.961 and SD: 0.049; <0.001). Beta regression showed that workers with a history of COVID-19 have greater protection compared to those without a history of the infection. Neutralizing antibodies were found to be decreased in alcoholic and diabetic subjects (80.1%). Notably, eight cases of Omicron reinfections were identified, and gender and obesity were associated with the presence of reinfections (6.41 OR; 95% BCa CI: 1.15, 105.0). The response to the vaccine was influenced by the history of SARS-CoV-2 infection and associated comorbidities. The above highlights the importance of prioritizing this segment of the population for reinforcements in periods of less than one year to guarantee their effectiveness against new variants.


Asunto(s)
COVID-19 , Vacunas , Humanos , SARS-CoV-2 , Anticuerpos Neutralizantes , COVID-19/epidemiología , COVID-19/prevención & control , Reinfección , Estudios Seroepidemiológicos , Personal de Salud , Anticuerpos Antivirales , Vacunación
3.
Am J Infect Control ; 51(1): 11-17, 2023 01.
Artículo en Inglés | MEDLINE | ID: mdl-35483519

RESUMEN

BACKGROUND: Medical devices can be reservoirs of multidrug-resistant bacteria that may be involved in the acquisition of infections since bacteria with the ability to form biofilms that are difficult to eradicate, mainly in mechanical ventilators. The aim of this work was to evaluate the efficacy of O3 against biofilms of bacteria ESKAPE group through disinfection studies. METHODS: The formation of biofilms of ESKAPE group bacteria was induced in vitro. O3 was injected at different exposure times at a constant dose of 600 mg/h. The recovery of surviving bacteria after O3 treatment was assessed by bacterial counts and biofilm disruption was analyzed. Finally, the viability and integrity of biofilms after O3 treatment was determined by confocal laser scanning microscopy (CLSM). RESULTS: O3 showed bactericidal activity on biofilms from 12 min/7.68 ppm for A. baumannii and C. freundii. P. aeruginosa, K. pneumoniae and S. aureus were killed after 15 min/9.60 ppm. Correlation analyses showed inversely proportional relationships between the variables "disruption versus O3". CLSM revealed that death was time-dependent of biofilms upon O3 exposure. Orthogonal plane analysis showed that bacteria located in the outer region of the biofilms were the ones that initially suffered damage from O3 exposure. CONCLUSIONS: Our findings suggest that this method could be an alternative for the disinfection in mechanical ventilators colonized by bacteria biofilm forming.


Asunto(s)
Desinfección , Ozono , Humanos , Desinfección/métodos , Staphylococcus aureus , Ozono/farmacología , Biopelículas , Bacterias , Antibacterianos/farmacología
4.
An. psicol ; 38(3): 448-457, Oct-Dic. 2022. tab, graf
Artículo en Inglés | IBECS | ID: ibc-208816

RESUMEN

Una de las consecuencias de la pandemia es el aumento de la prevalencia de alteraciones mentales como la ansiedad, la depresión y el estrés. En este estudio transversal y observacional se evaluó la prevalencia de estrés, ansiedad y depresión en pacientes hospitalizados por COVID-19 así como la probable asociación con el impacto emocional recibido por familiares de pacientes hospitalizados por COVID-19. Cuarenta y cinco pacientes hospitalizados por COVID-19 con una edad promedio de 54.4 ± 9.6 años y cincuenta y cinco familiares de pacientes hospitalizados con una edad promedio de 43.2 ± 11.8 años respondieron una batería de preguntas y la encuesta DASS-21. Nuestros resultados revelaron una alta prevalencia de depresión, ansiedad y estrés identificados por DASS-21. En este estudio identificamos factores de riesgo asociados a la salud emocional como la edad (< 50 años: depresión RM = 2.99 [1.31, 6.80] p < .05 y ansiedad RM = 2.83 [1.15, 6.93], p < .05), el género (mujeres: ansiedad RM = 4.13 [1.57, 10.89], p < .05 y estrés RM = 5.38 [2.27, 12.8], p < .05) y el grupo de estudio (familiares: depresión RM = 3.83 [1.63, 8.96]; p < .05 , ansiedad RM = 3.60 [1.46, 8.88]; p < .05 y estrés RM = 3.30 [1.41, 7.70]; p < .05). Además, el género femenino y el nivel socioeconómico bajo de los pacientes (β = 3.23; 1.96) y familiares (β = 1.86; 2.31) se asociaron con puntuaciones más altas en ansiedad (p < .05) y estrés (p < .05). Concluimos que la muestra de pacientes con COVID-19 mantiene una alta prevalencia de alteraciones mentales y que algunos factores sociodemográficos se asocian con la magnitud de estos trastornos.(AU)


One of the consequences of pandemic is the increase in the prevalence of mental alterations such as anxiety, depression and stress. Since here, we aimed to determinate through a transversal and observa-tional studyprevalence of stress, anxiety and depression within hospital-ized patients by COVID-19 as well as their likely association with the emo-tional impact received by relatives with hospitalized patients by COVID-19. Forty-five COVID-19 hospitalized patients with mean age of 54.4 ± 9.6 yearsand fifty-five relatives with mean age of 43.2 ± 11.8 yearsan-swered a questions battery and DASS-21 survey. Our resultsrevealed high prevalence of depression, anxiety and stress assessed by DASS-21 sub-scales. We also identified risk factors associated with the emotional health such as age (<50 years: depression OR=2.99 [1.31, 6.80], p< .05 and anxiety OR=2.83 [1.15,6.93], p< .05), by gender (female: anxiety OR = 4.13 [1.57, 10.89], p< .05 and stress OR = 5.38 [2.27, 12.8], p< .05), by group of study (relatives: depression OR = 3.83 [1.63, 8.96]; p< .05, anxie-ty OR = 3.60 [1.46, 8.88]; p< .05 and stress OR = 3.30 [1.41, 7.70]; p< .05). Additionally, female gender and low socioeconomic status in patients (β= 3.23; 1.96) and relatives (β= 1.86; 2.31) were associated with higher scores in anxiety (p< .05) and stress (p <.05). We concluded that our sample of COVID-19 patients maintain a high prevalence of mental altera-tions and age, gender and socioeconomic status modify the magnitude of these disorders.(AU)


Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Pacientes Internos , Salud Mental , Ansiedad/complicaciones , Ansiedad/tratamiento farmacológico , Trastornos de Ansiedad/diagnóstico , Estrés Psicológico , Depresión , Pandemias , Infecciones por Coronavirus/epidemiología , Factores de Riesgo , México , Psicología , Psicología Clínica , Medicina de la Conducta , Estudios Transversales , Infecciones por Coronavirus/complicaciones
5.
Front Med (Lausanne) ; 9: 913589, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35746947

RESUMEN

Ultrasound (US) of major salivary glands (MSG) evaluates echogenicity, border features and vascularization, with elastography, it can detect tissue elasticity and glandular fibrosis, related to inflammation in Primary Sjögren's syndrome (pSS). This study aimed to develop a novel technique by pixel analysis for evaluation and interpretation of elastography in MSG in pSS. A cross-sectional and observational multicenter study was conducted. The US of MSG performed in orthogonal planes in grayscale, Doppler, and shear-wave elastography. For elastography images of each gland were analyzed with the open-source program ImageJ to perform a pixel analysis. Statistical analysis was performed with the IBM-SPSS v25 program. Fifty-nine women with a mean age of 57.69 (23-83) years were recruited; pSS mean duration of 87 (5-275) months, and 12 healthy women without sicca symptoms as a control group with a mean age of 50.67 (42-60) years. Intragroup analysis showed p-values >0.05 between sicca symptoms, ocular/dryness tests, biopsy, US, and pixel analysis; correlation between Hocevar and pixel analysis was not found (rho < 0.1, p >0.5). MSG anatomical size was 41.7 ± 28.2 mm vs. 67.6 ± 8.8 mm (p ≤ 0.0001); unstimulated whole saliva flow rate was 0.80 ± 0.80 ml/5 min vs. 1.85 ± 1.27 ml/5 min (p = 0.016). The elastography values (absolute number of pixels) were 572.38 ± 99.21 vs. 539.69 ± 93.12 (p = 0.290). A cut-off point risk for pSS identified with less than 54% of red pixels in the global MSG mass [OR of 3.8 95% CI (1.01-15.00)]. Pixel analysis is a new tool that could lead to a better understanding of the MSG chronic inflammatory process in pSS.

6.
Can J Infect Dis Med Microbiol ; 2022: 6780575, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35494312

RESUMEN

Background: Evidence from across the world suggests that the pediatric population shows different clinical manifestations and has a lower risk of severe presentation of SARS-CoV-2 infection compared to adults. However, Mexico has one of the highest mortality rates in the pediatric population due to SARS-CoV-2 infection. Therefore, our objective was to explore the epidemiological and clinical characteristics associated with a positive confirmatory test in the Mexican pediatric population admitted to a tertiary care hospital in Mexico City. Methods: Clinical, imaging and laboratory data were retrospectively collected from 121 children hospitalized during the period from March 4th, 2020, to August 8th, 2021. The patients were identified as suspicious cases according to the guidelines of the General Directorate of Epidemiology of Mexico. Real-time polymerase chain reaction (RT-PCR) tests were used to confirm SARS-CoV-2 infection. Categorical variables were compared using the Chi-square test, and propensity score matching was performed to determine univariate and multivariate odds ratios of the population regarding a positive vs. negative SARS-CoV-2 result. Results: Of the 121 children, 36 had laboratory-confirmed SARS-CoV-2 infection. The main risk for SARS-CoV-2-associated pediatric hospitalization was contact with a family member with SARS-CoV-2. It was also found that fever and fatigue were statistically significantly associated with a positive SARS-CoV-2 test in multivariate models. Clinical and laboratory data in this Mexican hospitalized pediatric cohort differ from other reports worldwide; the mortality rate (1.6%) of the population studied was higher than that seen in reports from other countries. Conclusion: Our study found that fever and fatigue at hospital presentation as well as an antecedent exposure to a family member with SARS-CoV-2 infection were important risk factors for SARS-CoV-2 positivity in children at hospital admission.

7.
J Patient Saf ; 17(8): e1889-e1893, 2021 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-32398539

RESUMEN

INTRODUCTION: The objective of this work is to measure the economic and epidemiological impact of the implementation of a comprehensive quality improvement plan (CQIP) for the prevention and reduction of ventilator-associated pneumonia (VAP) in the adult intensive care unit in a Mexican hospital. MATERIALS AND METHODS: A cross-sectional, ambispective, comparative, analytical, observational study was conducted with epidemiological data on cases of health care-associated infections and with information from the Hospital Epidemiological Surveillance Unit from August 2017 to July 2018. RESULTS: Before to the implementation of the CQIP, there were a total of 26 VAPs, with a rate of 32.2 per 1000 ventilator-days. After the implementation of CQIP, there were 14 VAPs, with a rate of 23.4 per 1000 ventilator-days, with a 46.2% decrease in incidence (P = 0.02). Before the installation of the interventions, the expense was $4,471,073.80, with an average cost per case of $171,964.38. The total cost per bed-day in the adult intensive care unit was $331,280.00, and for hospitalization, the cost was $192,038.00; for the use of antimicrobials, an expense of $749,689.20 was calculated, and for the use of mechanical ventilation, the cost was $2,974,275.60. The percentage of decrease in the cost of VAP after CQIP implementation was 46.5%. CONCLUSIONS: The implementation of CQIP based on the risk evaluation factors of VAP resulted in their decrease, which is reflected in a patient safety and quality care improvement.


Asunto(s)
Neumonía Asociada al Ventilador , Adulto , Estudios Transversales , Humanos , Incidencia , Unidades de Cuidados Intensivos , México/epidemiología , Neumonía Asociada al Ventilador/epidemiología , Neumonía Asociada al Ventilador/prevención & control , Centros de Atención Terciaria
8.
Rev Panam Salud Publica ; 44: e45, 2020.
Artículo en Español | MEDLINE | ID: mdl-32973898

RESUMEN

OBJECTIVE: Describe the results of the Program for the Rational Use of Antimicrobials at Mexico's Juárez Hospital. METHODS: An observational, cross-sectional, retrospective, descriptive study was designed. For the consumption of antimicrobial agents, data from January 2013 to December 2018 were analyzed by calculating the defined daily dose (DDD). For the cost analysis, a traditional costing calculation was used. RESULTS: For the group of carbapenem agents, there was a sizeable reduction in the consumption of imipenem / cilastatin: the DDD declined from 2.3 in 2013 to 0.7 in 2018, a decrease of 70%. By contrast, for the other two agents, increases were observed. The consumption of meropenem increased by 2% (from 2.4 in 2013 to 2.5 in 2018); the consumption of ertapenem increased by 75% (from 1 in 2013 to 1.8 in 2018). The total expenditure on antimicrobial agents was USD 930 556.46 during 2013, compared to USD 856 079.10 during 2018, representing a difference of 8% or USD 74 905.61 of the total expenditure. CONCLUSIONS: Programs for the rational use of antimicrobials need to be evaluated continuously, by monitoring both consumption of agents by patients and related institutional expenditures.


OBJETIVO: Descrever os resultados do Programa para o Uso Racional de Antimicrobianos no Hospital Juárez de México. MÉTODOS: Elaboramos um estudo observacional, transversal, retrospectivo e descritivo. Analisamos o consumo de antimicrobianos de janeiro de 2013 a dezembro de 2018 pelo cálculo da dose diária definida (DDD); para a análise de custos, realizamos um cálculo de custos tradicional. RESULTADOS: No grupo dos carbapenens, a redução do consumo de imipenem/cilastatina foi notável: passou-se de uma DDD de 2,3 em 2013 para 0,7 em 2018, uma redução de 70%. Por outro lado, observou-se um aumento no uso dos dois outros medicamentos: no caso do meropenem, foi registrado um aumento de 2% (de 2,4 em 2013 a 2,5 em 2018); no consumo de ertapenem o aumento foi de 75% (de 1 em 2013 a 1,8 em 2018). No total, as despesas com antimicrobianos foram de USD 930 556,46 em 2013 e de USD 856 079,10 em 2018, uma diferença de 8%, o que equivale a uma redução de USD 74 905,61 nas despesas totais. CONCLUSÕES: É necessário avaliar continuamente os programas para o uso racional de antimicrobianos pelo monitoramento do consumo e das despesas derivadas.

9.
Cir Cir ; 88(Suppl 1): 59-62, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32963392

RESUMEN

Las manifestaciones neuropsiquiátricas en los pacientes con lupus eritematoso sistémico (LES) y síndrome antifosfolípido (SAF) secundario son muy frecuentes. En ambos casos, la fisiopatología se correlaciona con vasculopatía asociada a anticuerpos antifosfolípido y neurotoxicidad por anticuerpos y citocinas. La corea es el único trastorno del movimiento incluido en los 19 síndromes neuropsiquiátricos del LES según el American College of Rheumatology, con presentación inusual (prevalencia del 2%), y puede ocurrir como primera manifestación de la enfermedad. Se describe el caso de una paciente de 17 años con corea desencadenada durante el embarazo como manifestación inicial de LES y SAF.Neuropsychiatric symptoms of systemic lupus erythematosus (SLE) and secondary antiphospholipid syndrome (APS) are very common. In both cases, pathophysiology is correlated to vasculopathy associated to antiphospholipid antibodies as well as neurotoxicity mediated by antibodies and cytokines. Chorea, instead, is the only movement disorder included in the 19 SLE's neuropsychiatric syndromes described by the American College of Rheumatology. Nevertheless, its presence is unusual with a prevalence of about 2%, and could appear as an early manifestation of the disease. The case of a 17-year-old pregnant woman in whom chorea was an early manifestation of SLE and APS.


Asunto(s)
Síndrome Antifosfolípido , Corea Gravidarum , Lupus Eritematoso Sistémico , Adolescente , Síndrome Antifosfolípido/complicaciones , Femenino , Humanos , Lupus Eritematoso Sistémico/complicaciones , Embarazo , Estados Unidos
10.
Cir Cir ; 88(Suppl 1): 112-115, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32963398

RESUMEN

La granulomatosis con poliangeítis es una vasculitis de pequeños vasos asociada a la presencia de anticuerpos anticitoplasma de neutrófilos, con manifestaciones cardíacas que son poco frecuentes, como pericarditis, miocarditis, arteritis coronaria y enfermedad valvular. Reportamos el caso de un paciente de 49 años con reciente diagnóstico de granulomatosis con poliangeítis, quien presentó infarto agudo del miocardio. Se consideró la actividad de la enfermedad como causa del infarto. Las manifestaciones clínicas cardiovasculares en la granulomatosis con poliangeítis son relevantes por ser marcadores de mal pronóstico.Granulomatosis with polyangiitis is a small vessel vasculitis associated to anti-neutrophil cytoplasmic antibodies, in which the cardiac manifestations are not common, as pericarditis, cardiomyopathy, coronary artery disease and vascular disease. We report a clinical case of a 49-year-old man with a recent diagnosis of granulomatosis with polyangiitis, he presented myocardial infarction. Disease activity was considered the cause of myocardial infarction. Cardiovascular clinical manifestations in granulomatosis with polyangiitis are relevant because are markers of poor prognosis.


Asunto(s)
Granulomatosis con Poliangitis , Infarto del Miocardio , Granulomatosis con Poliangitis/complicaciones , Granulomatosis con Poliangitis/diagnóstico , Humanos , Masculino , Persona de Mediana Edad , Infarto del Miocardio/etiología
11.
Rev Panam Salud Publica ; 44, sept. 2020
Artículo en Español | PAHO-IRIS | ID: phr-52312

RESUMEN

[RESUMEN]. Objetivo. Describir los resultados del Programa de Uso Racional de Antimicrobianos en el Hospital Juárez de México. Métodos. Se diseñó un estudio de tipo observacional, transversal, retrospectivo y descriptivo. Se analizó el consumo de antimicrobianos de enero de 2013 a diciembre de 2018 a través del cálculo de la dosis diaria definida (DDD); para el análisis de costos se realizó un cálculo de costeo tradicional. Resultados. En el grupo de los carbapenémicos, es notable la reducción en el consumo de imipenem/cilastina: se pasó de una DDD en el 2013 de 2,3 a 0,7 en el 2018, con una reducción de 70%. En cambio, en los otros dos fármacos, se ha observado un incremento. En meropenem se registró de 2% (de 2,4 en 2013 a 2,5 en 2018); en el consumo de ertapenem el incremento es de 75% (de 1 en 2013 a 1,8 en 2018). En total, el gasto de antimicrobianos durante 2013 fue de $930 556,46, mientras que en 2018 fue de $856 079,10, con una diferencia de 8%, lo que equivale a $74 905,61 del gasto total (los valores se expresan en dólares estadounidenses). Conclusiones. Se necesita evaluar de manera constante los programas para el uso racional de antimicrobianos, mediante el monitoreo del consumo y el gasto derivado.


[ABSTRACT]. Objective. Describe the results of the Program for the Rational Use of Antimicrobials at Mexico’s Juárez Hospital. Methods. An observational, cross-sectional, retrospective, descriptive study was designed. For the consumption of antimicrobial agents, data from January 2013 to December 2018 were analyzed by calculating the defined daily dose (DDD). For the cost analysis, a traditional costing calculation was used. Results. For the group of carbapenem agents, there was a sizeable reduction in the consumption of imipenem / cilastatin: the DDD declined from 2.3 in 2013 to 0.7 in 2018, a decrease of 70%. By contrast, for the other two agents, increases were observed. The consumption of meropenem increased by 2% (from 2.4 in 2013 to 2.5 in 2018); the consumption of ertapenem increased by 75% (from 1 in 2013 to 1.8 in 2018). The total expenditure on antimicrobial agents was USD 930 556.46 during 2013, compared to USD 856 079.10 during 2018, representing a difference of 8% or USD 74 905.61 of the total expenditure. Conclusions. Programs for the rational use of antimicrobials need to be evaluated continuously, by monitoring both consumption of agents by patients and related institutional expenditures.


[RESUMO]. Objetivo. Descrever os resultados do Programa para o Uso Racional de Antimicrobianos no Hospital Juárez de México. Métodos. Elaboramos um estudo observacional, transversal, retrospectivo e descritivo. Analisamos o consumo de antimicrobianos de janeiro de 2013 a dezembro de 2018 pelo cálculo da dose diária definida (DDD); para a análise de custos, realizamos um cálculo de custos tradicional. Resultados. No grupo dos carbapenens, a redução do consumo de imipenem/cilastatina foi notável: passou-se de uma DDD de 2,3 em 2013 para 0,7 em 2018, uma redução de 70%. Por outro lado, observou-se um aumento no uso dos dois outros medicamentos: no caso do meropenem, foi registrado um aumento de 2% (de 2,4 em 2013 a 2,5 em 2018); no consumo de ertapenem o aumento foi de 75% (de 1 em 2013 a 1,8 em 2018). No total, as despesas com antimicrobianos foram de USD 930 556,46 em 2013 e de USD 856 079,10 em 2018, uma diferença de 8%, o que equivale a uma redução de USD 74 905,61 nas despesas totais. Conclusões. É necessário avaliar continuamente os programas para o uso racional de antimicrobianos pelo monitoramento do consumo e das despesas derivadas.


Asunto(s)
Antiinfecciosos , Farmacoepidemiología , Farmacorresistencia Microbiana , México , Antiinfecciosos , Farmacoepidemiología , Farmacorresistencia Microbiana , México , Antiinfecciosos , Farmacoepidemiología , Farmacorresistencia Microbiana
12.
Clin Rheumatol ; 39(7): 2245, 2020 07.
Artículo en Inglés | MEDLINE | ID: mdl-32385762

RESUMEN

Following publication, it was brought to the authors' attention by Dr. Julia Toscano-Garibay that she did not participate as a reviewer of the final version of this manuscript prior to its submission and publication in Clinical Rheumatology.

14.
Artículo en Inglés | MEDLINE | ID: mdl-31388340

RESUMEN

BACKGROUND: Neutrophils play an important role in the pathogenesis of rheumatoid arthritis (RA). It has recently been reported that in addition to T helper (Th) 17 cells, other cells, including neutrophils, produce IL-17A, an important inflammatory cytokine involved in the pathogenesis of RA. The purpose of this study was to examine the presence of interleukin 17A-producing neutrophils in patients with RA. METHODS: We performed a cross-sectional study including 106 patients with RA and 56 healthy individuals. Whole peripheral blood cells were analyzed by flow cytometry to identify CD66b+ CD177+ IL-17A+ neutrophils and CD3+ CD4+ IL-17A+ T cells. Serum levels of IL-17A and IL-6 were measured by means of cytometry bead array (CBA). In purified neutrophils, mRNA levels of IL-17 and RORγ were measured by RT-PCR. In addition, purified neutrophils from patients and healthy controls were stimulated with the cytokines IL-6 and IL-23 to evaluate differences in their capacity to produce IL-17A. RESULTS: Neutrophils from RA patients expressed IL-17 and RORγ mRNA. Consequently, these cells also expressed IL-17A. Serum IL-17A levels but not Th17 cell numbers were increased in RA patients. Neutrophils positive for cytoplasmic IL-17A were more abundant in patients with RA (mean 1.2 ± 3.18%) than in healthy individuals (mean 0.07 ± 0.1%) (p < 0.0001). Although increased IL-17A+ neutrophil numbers were present in RA patients regardless of disease activity (mean 6.5 ± 5.14%), they were more frequent in patients with a more recent diagnosis (mean time after disease onset 3.5 ± 4.24 years). IL-6 and IL-23 induced the expression of RORγ but failed to induce IL-17A expression by neutrophils from RA patients and healthy individuals after a 3 h stimulation. CONCLUSION: IL-17A-producing neutrophils are increased in some RA patients, which are not related to disease activity but have an increased frequency in patients with recent-onset disease. This finding suggests that IL-17A-producing neutrophils play an early role in the development of RA.

15.
Med. interna Méx ; 35(2): 268-272, mar.-abr. 2019. graf
Artículo en Español | LILACS-Express | LILACS | ID: biblio-1135173

RESUMEN

Resumen LA enfermedad de Poncet es una poliartritis aséptica reactiva poco frecuente que ocurre durante cualquier etapa de una infección activa pulmonar o extrapulmonar por Mycobacterium tuberculosis. Existen apenas 200 casos descritos en la bibliografía y hasta el momento permanece como diagnóstico de exclusión sin patogenia bien definida. Suele responder rápida y satisfactoriamente al tratamiento antituberculoso sin dejar secuelas. Este artículo revisa la epidemiología, patogenia, manifestación clínica, diagnóstico, tratamiento y pronóstico de la enfermedad de Poncet.


Abstract Poncet's disease is a rarely reported aseptic reactive polyarthritis associated to active pulmonary or extrapulmonary infection caused by Mycobacterium tuberculosis. There are no more than 200 cases reported in the literature and still remains as a diagnosis of exclusion with unknown pathogenesis. It quickly and remarkably resolves with antituberculous drugs, has usually a good prognosis and does not turn into chronic arthritis. This article reviews the epidemiology, pathogenesis, clinical presentation, diagnosis, treatment options and prognosis of Poncet's disease.

16.
Clin Rheumatol ; 37(4): 901-908, 2018 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-29256110

RESUMEN

The aim of the is study is to examine the role of serum substance P (SP) levels as a simple biomarker for rheumatoid arthritis (RA) disease activity, its correlation with other markers of disease activity, and with selected clinical parameters. The study comprised 90 RA patients and 24 healthy controls. RA activity was assessed by means of the disease activity 28-C-reactive protein (DAS28-CRP) index and ultrasound power Doppler (USPD) by the German ultrasound score based on seven joints. SP serum values were obtained by means of an ELISA commercial kit. Statistics were achieved by the Student's t test and Spearman correlation analysis with Bonferroni correction. As a group, RA patients had significantly increased levels of SP compared with healthy controls (p < 0.0001). SP levels correlated with DAS28-CRP (r = 0.5050, p < 0.0001), number of tender joints (NTJ, r = 0.4668, p < 0.0001), number of swollen joints (NSJ, r = 0.4439, p < 0.0001), visual analogue scale (VAS, r = 0.5131, p < 0.0001). However, SP did not correlate with CRP levels (r = 0.0468, p = 0.6613), nor with the USPD (r = 0.1740, p = 0.1009). Elevated serum SP is a common feature of RA patients, which also appears to correlate with clinical measurements of disease activity and with subjective clinical data (NTJ and VAS). Thus, although SP is higher in RA patients with high disease activity, it also detects subtle RA disease activity even in patients in apparent remission, which suggests its usefulness for therapeutic decisions.


Asunto(s)
Artritis Reumatoide/diagnóstico , Inflamación/diagnóstico , Sustancia P/sangre , Adulto , Artritis Reumatoide/sangre , Biomarcadores/sangre , Proteína C-Reactiva/metabolismo , Femenino , Humanos , Inflamación/sangre , Masculino , Persona de Mediana Edad , Índice de Severidad de la Enfermedad , Ultrasonografía , Adulto Joven
17.
Cir Cir ; 84(2): 169-72, 2016.
Artículo en Español | MEDLINE | ID: mdl-26255767

RESUMEN

BACKGROUND: Deaths due to tuberculosis have reached 2.5 million cases per year worldwide. Poncet's disease is an infrequent form of tuberculosis characterised by a clinical picture of polyarthritis. CLINICAL CASE: A 24-year-old male presented with morning stiffness, arthralgias, bilateral symmetric arthritis of the proximal interphalangeal joints, wrists, knees, ankles, and shoulders, and adenomegalies at the cervical, submandibular, left supraclavicular, axillary and inguinal levels, without fever. Laboratory results were as follows: ESR 44mm/h, C-reactive protein 4.35, normal levels of complement C3 and C4, negative rheumatoid factor and anticyclic citrullinated peptide antibodies, positive antinuclear antibodies with fine speckled pattern (1:320) and cytoplasm (1:160) pattern and negative anti-Smith, -double-stranded DNA, Sjogren's syndrome-antigen A and Sjogren's syndrome-antigen B. Histological report of cervical node tissue revealed granulomatous lesions compatible with tuberculosis. Rheumatoid arthritis and systemic lupus erythematosus were ruled out. Anti-tuberculosis agents were initiated that resolved the clinical picture. Diagnosis of Poncet's disease was confirmed. CONCLUSION: The differential diagnosis between tuberculosis and autoimmune inflammatory joint diseases is a clinical challenge.


Asunto(s)
Artritis Reactiva/microbiología , Tuberculosis Osteoarticular , Artritis Reactiva/diagnóstico , Humanos , Masculino , Enfermedades Reumáticas/diagnóstico , Enfermedades Reumáticas/microbiología , Tuberculosis Osteoarticular/diagnóstico , Adulto Joven
18.
Reumatol. clín. (Barc.) ; 3(4): 166-170, jul.-ago. 2007. ilus, tab
Artículo en Español | IBECS | ID: ibc-77683

RESUMEN

Objetivo: Analizar 11 casos de policondritis recidivante reportados por 3 centros hospitalarios de México. Pacientes y método: Se analiza sexo, edad a la presentación de la enfermedad, tiempo de evolución al momento del diagnóstico, manifestaciones clínicas iniciales y durante el seguimiento, tratamiento inicial, así como el esquema terapéutico empleado en la fase “crónica” de la enfermedad. Resultados: Se describió a 8 mujeres y 3 varones con edad promedio al inicio de 40,8 años. El tiempo de evolución al momento del diagnóstico fue de 4 meses a 4 años. Las principales manifestaciones fueron: condritis auricular en 8 (72,7%) de los casos, hipoacusia en 4 (36,3%) y disfonía en 4 (36,3%). Las complicaciones incluyeron estenosis subglótica en 4 (36,3%) pacientes, epiescleritis en 2 (18,1%), y desprendimiento de retina y córnea con lesión macular en 1 (9%); 2 (18,1%) tuvieron hipoacusia conductiva y sensorial; 2 (18,1%), glomerulonefritis y 1 (9%), insuficiencia mitral y tricuspídea. Todos los pacientes recibieron tratamiento a base de prednisona. Los inmunosupresores más usados fueron: ciclofosfamida, metotrexato y azatioprina. Conclusiones: Ésta es la mayor serie publicada en México y comparte datos clínicos y de evolución comunicados en otras series y en la literatura. La respuesta a esteroides es buena; sin embargo, es necesario considerar otras opciones terapéuticas, ya que la enfermedad continúa progresando y recidivando (AU)


Objective: To analyze 11 patients with relapsing polychondritis reported by 3 hospitals in our country. Patients and method: We describe 11 cases of relapsing polychondritis reported by 3 hospitals in our country, analizing gender, age at the beginning of the disease, delay time in diagnosis, clinical manifestations at the beginning of the disease and during follow-up, initial treatment, and treatment in the “chronic phase” of the disease. Results: We described 8 female patients and 4 males, with a mean age of 40.8 years. The delay time in diagnosis was from 4 months to 4 years. The main manifestations were: auricular chondritis in 8 patients (72.7%), hearing loss in 4 (36.3%), and dysphonia in 4 (36.3%). The complications included subglotic stenosis in 4 patients (36.3%), epiescleritis in 2 (18.1%), 1 retinal and corneal dettachment with macular lesion (9%), conductive and sensorial hearing loss in 2 (18.1%), glomerulonephritis in 2 (18.1%), and mitral and tricuspid insufficiency in one patient (9.0%). All of them received prednisone. Cyclophosphamide, methotrexate, and azathioprine were the most common immunosupressors used. Conclusions: This is the largest cohort reported in our country, sharing clinical and outcome patterns reported in other series and in the literature. Response to steroids is good, however, we need to consider other therapeutic options because the disease continues progressing and relapsing (AU)


Asunto(s)
Humanos , Masculino , Femenino , Policondritis Recurrente/diagnóstico , Enfermedades de los Cartílagos/diagnóstico , Esteroides/uso terapéutico , Trastornos de la Voz/epidemiología , Pérdida Auditiva/epidemiología , Laringoestenosis/complicaciones , Escleritis/complicaciones , Desprendimiento de Retina/complicaciones
19.
Reumatol Clin ; 3(4): 166-70, 2007 Jul.
Artículo en Español | MEDLINE | ID: mdl-21794422

RESUMEN

OBJECTIVE: To analyze 11 patients with relapsing polychondritis reported by 3 hospitals in our country. PATIENTS AND METHOD: We describe 11 cases of relapsing polychondritis reported by 3 hospitals in our country, analizing gender, age at the beginning of the disease, delay time in diagnosis, clinical manifestations at the beginning of the disease and during follow-up, initial treatment, and treatment in the "chronic phase" of the disease. RESULTS: We described 8 female patients and 4 males, with a mean age of 40.8 years. The delay time in diagnosis was from 4 months to 4 years. The main manifestations were: auricular chondritis in 8 patients (72.7%), hearing loss in 4 (36.3%), and dysphonia in 4 (36.3%). The complications included subglotic stenosis in 4 patients (36.3%), epiescleritis in 2 (18.1%), 1 retinal and corneal dettachment with macular lesion (9%), conductive and sensorial hearing loss in 2 (18.1%), glomerulonephritis in 2 (18.1%), and mitral and tricuspid insufficiency in one patient (9.0%). All of them received prednisone. Cyclophosphamide, methotrexate, and azathioprine were the most common immunosupressors used. CONCLUSIONS: This is the largest cohort reported in our country, sharing clinical and outcome patterns reported in other series and in the literature. Response to steroids is good, however, we need to consider other therapeutic options because the disease continues progressing and relapsing.

20.
Rev. mex. reumatol ; 13(5): 249-51, sept.-oct. 1998. ilus
Artículo en Español | LILACS | ID: lil-241078

RESUMEN

La policondritis recidivante (RP) es una enfermedad inflamatoria multisistémica caracterizada por lesión del cartílago, oídos, articulaciones y laringe. Su etiología es desconocida. Informamos de un paciente masculino de 48 años de edad, con dos meses de condritis auricular, proteinuria y alteraciones en la audición. La biopsia de cartílago mostró inflamación crónica. El tratamiento con prednisona fue efectivo para suprimir las manifestaciones agudas; sin embargo, ante la progresión del daño renal se administró azatioprina


Asunto(s)
Humanos , Masculino , Persona de Mediana Edad , Policondritis Recurrente/diagnóstico , Policondritis Recurrente/fisiopatología , Policondritis Recurrente/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA